Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Medexus Pharmaceuticals Inc (MDP – Research Report), with a price target of C$6.00.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
David Martin PhD has given his Buy rating due to a combination of factors including Medexus Pharmaceuticals Inc’s recent financial performance and promising product developments. The company’s revenues and EBITDA have met expectations, indicating stable financial health.
Additionally, the early signs from the launch of Grafapex are positive, suggesting potential for future growth. These elements together contribute to a favorable outlook for Medexus, justifying the Buy recommendation.
In another report released on June 27, Raymond James also maintained a Buy rating on the stock with a C$8.00 price target.
MDP’s price has also changed slightly for the past six months – from C$3.300 to C$3.150, which is a -4.55% drop .